Ming Su
Impact in
- Hepatology top 10%
- Hepatitis C virus research
- Cancer Research top 10%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Papers in
-
- Hepatocellular Carcinoma Treatment and Prognosis 8
- Epidemiology 17
- Autophagy in Disease and Therapy 6
- Hepatitis B Virus Studies 5
- Liver Disease Diagnosis and Treatment 3
- Co-authors
- Rutai Hui (6 shared papers)Lei Song (4 shared papers)Wei Qiu (10 shared papers)Jizheng Wang (3 shared papers)Yubao Zou (3 shared papers)Mei Jia (12 shared papers)Yilu Wang (2 shared papers)Yibo Wang (1 shared paper)
- Journals
- DNA and Cell Biology (6 papers)Disease Markers (5 papers)Cell Biochemistry and Biophysics (3 papers)Chemistry & Biodiversity (1 paper)Cell Death and Disease (1 paper)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Ming Su
52 papers receiving 1.1k citations
Ming Su's Hit Papers
Peers
Comparison fields: 5 of 99
- Hepatology 118
- Cancer Research 180
- Epidemiology 310
- Biotechnology 49
- Cardiology and Cardiovascular Medicine 118
Countries citing papers authored by Ming Su
This map shows the geographic impact of Ming Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming Su more than expected).
Fields of papers citing papers by Ming Su
This network shows the impact of papers produced by Ming Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming Su. The network helps show where Ming Su may publish in the future.
Co-authors
The 25 scholars most cited alongside Ming Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 60 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2014 | 147 | |
| 2 | 2014 | 107 | |
| 3 | 2011 | 100 | |
| 4 | 2014 | 86 | |
| 5 | 2019 | 51 | |
| 6 | The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy Hit paper breakdown → | 2025 | 48 |
| 7 | 2004 | 48 | |
| 8 | 2016 | 48 | |
| 9 | 2016 | 47 | |
| 10 | 2014 | 41 | |
| 11 | 2017 | 35 | |
| 12 | 2013 | 27 | |
| 13 | 2022 | 23 | |
| 14 | 2021 | 20 | |
| 15 | 2001 | 19 | |
| 16 | 2019 | 19 | |
| 17 | 2016 | 18 | |
| 18 | 2018 | 18 | |
| 19 | 2019 | 17 | |
| 20 | 2019 | 16 |
About Ming Su
Ming Su is a scholar working on Hepatology, Epidemiology, Cancer Research, Biotechnology and Pulmonary and Respiratory Medicine, having authored 60 papers that have together received 1.1k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (8 papers), Autophagy in Disease and Therapy (6 papers), Ubiquitin and proteasome pathways (5 papers), Hepatitis B Virus Studies (5 papers), Microbial Inactivation Methods (3 papers), Liver Disease Diagnosis and Treatment (3 papers), MicroRNA in disease regulation (2 papers) and Invertebrate Immune Response Mechanisms (2 papers). The work is most often cited by research in Hepatology (118 citations), Cancer Research (180 citations), Epidemiology (310 citations), Biotechnology (49 citations) and Cardiology and Cardiovascular Medicine (118 citations). Ming Su has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Rutai Hui, Lei Song, Wei Qiu, Jizheng Wang, Yubao Zou, Mei Jia, Yilu Wang, Yibo Wang, Weijie Dong and Chang-Xin Wang. Their work appears in journals such as DNA and Cell Biology, Disease Markers, Cell Biochemistry and Biophysics, Chemistry & Biodiversity and Cell Death and Disease.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.